



ASX Release (ASX: MEM)

SETTLEMENT OF DISPUTE BETWEEN MEMPHASYS AND TRANSOCEAN SECURITIES

Sydney, Friday, 8 September 2017

The directors of Memphasys Limited (the Company) wish to advise that the dispute between the Company and Transocean Securities Pty Ltd, which was referred to in an announcement dated 21 November 2016, has been settled at mediation. The terms of the settlement are confidential.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556